EKSO Ekso Bionics Holdings Inc

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Ekso Bionics Holdings, Inc. (EKSO) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) securities between March 15, 2017 and December 27, 2017 (the “Class Period”). Investors have until March 5, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On December 14, 2017, Ekso announced that "the Company's internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date." Following this news, Ekso's share price fell $0.15, or 6.17%, to close at $2.28 on December 15, 2017.

On December 27, 2017, post-market, Ekso filed its amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. The following trading day, shares of Ekso fell $0.34, or 13.2%, to close at $2.23 per share on December 28, 2017.

The complaint alleges that, throughout the class period, defendants made false and/or misleading statements and/or failed to disclose that: (1) there was a material weakness in Ekso’s internal control over financial reporting and Ekso’s disclosure controls and procedures were not effective; and (2) as a result, Defendants public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired Ekso securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Ekso Bionics lawsuit, please go to http://www.bespc.com/ekso. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
03/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE

Ekso Bionics Prices $5.852 million Private Placement

Ekso Bionics Prices $5.852 million Private Placement SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company’s Series B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of common stock o...

 PRESS RELEASE

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor o...

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s rehabilitation system in the United States. The Bal...

 PRESS RELEASE

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Comm...

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering...

 PRESS RELEASE

Ekso Bionics Reports Third Quarter 2025 Financial Results

Ekso Bionics Reports Third Quarter 2025 Financial Results SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2 millionGross margin increased 680 basis points year-over-year and 2,050 basis points sequential...

 PRESS RELEASE

Ekso Bionics Reports Second Quarter 2025 Financial Results

Ekso Bionics Reports Second Quarter 2025 Financial Results SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, suppor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch